FDA announcement that Missouri firm Divinity Products will recall and destroy kratom was part of the agency's latest warning that ingredients derived from the herb are not safe for use in supplements or for therapeutic use to treat symptoms of withdrawal from opioid abuse. FDA doesn't get agreement from the kratom sector about the herb's status as a dietary ingredient as well as its safety profile.
One of the two latest strikes against marketing kratom in the US is a Missouri firm that previously touted the herb's safety and benefits agreeing with FDA to destroy its product inventory.
A second strike is reports of eight people hospitalized after using potentially salmonella-contaminated products containing the ingredient (see box below).
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
